Você procurou por: nstemi (Esloveno - Inglês)

ua/ nstemi
ua/ nstemi

ua/ nstemi primarni sestavljeni izidi
ua/ nstemi primary composite outcome events

tudi pri ogroženih bolnikih z ua/ nstemi, ki zahtevata urgentno
these are

pri bolnikih z ua/nstemi in stemi so pogosto poročali o krvavitvah.
bleeding was a commonly reported event in patients with ua/nstemi and stemi.

tveganje za krvavitve, povezano z izbiro časa za dajanje polnilnega odmerka pri nstemi
bleeding risk associated with timing of loading dose in nstemi

preprečevanje vte in zdravljenje ua/nstemi in stemi - prilagajanje odmerka ni potrebno.
prevention of vte and treatment of ua/nstemi and stemi - dosing adjustment of fondaparinux is not necessary.

v ključnem kliničnem preskušanju ua/ nstemi, zdravljenja s fondaparinuksom niso uvedli prej kot 2 uri po
in the pivotal ua/ nstemi clinical trial, treatment with fondaparinux was restarted no earlier than 2 hours after sheath removal.

v študiji iii. faze ua/ nstemi so najpogosteje poročali o naslednjih neželenih učinkih, ki niso bili
4.1% (enoxaparin) up to and including day 9 in the phase iii ua/ nstemi study, and the incidence of adjudicated severe hemorrhage by modified timi criteria was 1.1% (fondaparinux) vs.

10.057 bolnikih, ki so se zdravili zaradi akutnega koronarnega sindroma (ua ali nstemi).
10,057 patients undergoing treatment of ua or nstemi acs

- z akutnim koronarnim sindromom (nestabilna angina pektoris, nstemi in stemi) (glejte
− an acute coronary syndrome (unstable angina, nstemi and stemi) (see section 4.4)

tudi pri ogroženih bolnikih z ua/nstemi, ki zahtevata urgentno revaskularizacijo, uporabe fondaparinuksa pred in med pci ne priporočamo.
similarly, in ua/nstemi patients with life threatening conditions that require urgent revascularisation, the use of fondaparinux prior to and during pci is not recommended.

bolniki v kraku a študije acuity so prejemali nefrakcionirani heparin ali enoksaparin, ki so ga dajali v skladu z veljavnimi smernicami za vodenje aks pri bolnikih z ua in nstemi.
in arm a of the acuity trial, ufh or enoxaparin was administered in accordance with the relevant guidelines for the management of acs in patients with ua and nstemi.

preprečevanje vte in zdravljenje ua/nstemi in stemi - bolniki s telesno maso < 50 kg imajo povečano tveganje za krvavitev.
prevention of vte and treatment of ua/nstemi and stemi - patients with body weight <50 kg are at increased risk of bleeding.

z akutnim koronarnim sindromom (nestabilna angina pektoris, nstemi in stemi) (glejte poglavje 4.4)
an acute coronary syndrome (unstable angina, nstemi and stemi) (see section 4.4)

vsi bolniki so bili standardno zdravljeni za ua/nstemi, pci je bila izvedena pri 34 % bolnikov, cabg pa pri 9 % bolnikov.
all patients received standard medical treatment for ua/nstemi, with 34% of patients undergoing pci and 9% undergoing cabg.

pri približno 20. 000 bolnikih z ua/ nstemi je primerjala uporabo fondaparinuksa v odmerku 2, 5 mg subkutano enkrat na dan in enoksaparina v odmerku 1 mg/ kg subkutano dvakrat na dan.
treatment of unstable angina or non-st segment elevation myocardial infarction (ua/ nstemi) oasis 5 was a double-blind, randomised, non-inferiority study with fondaparinux 2.5 mg subcutaneously once daily versus enoxaparin 1 mg/ kg subcutaneously twice daily in approximately 20,000 patients with ua/ nstemi.

pri približno 20. 000 bolnikih z lje ua/ nstemi je primerjala uporabo fondaparinuksa v odmerku 2, 5 mg subkutano enkrat na dan in enoksaparina v odmerku 1 mg/ kg subkutano dvakrat na dan.
all patients received standard medical treatment for ua/ nstemi,

pri zdravljenju ua/nstemi in stemi, je treba fondaparinuks uporabljati previdno pri bolnikih, ki se sočasno zdravijo z drugimi zdravili, ki povečajo tveganje za krvavitve (kot so zaviralci gpiib/iiia ali trombolitiki).
for treatment of ua/nstemi and stemi, fondaparinux should be used with caution in patients who are being treated concomitantly with other agents that increase the risk of haemorrhage (such as gpiib/iiia inhibitors or thrombolytics).